anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Thermodynamic consequences of a three-hour long anoxia were investigated on the isolated mammalian rat myocardium. The anoxic heart operated in a far-from-equilibrium manner as attested by the non-linearity between the thermodynamic force and the thermodynamic flow. When subjected to slight fluctuations due to anoxia, the open far-from-equilibrium cardiac system presented a thermodynamic bifurcation at ~ 60 minutes of anoxia. The bifurcation was characterized by a sudden change of direction in the bifurcation diagram of a one-dimensional nonlinear differential equation with one parameter and occurred at a non-hyperbolic fixed point at which moment the heart lost its thermodynamic stability. The parameter of the differential equation was the single force of the myosin molecular motor. These results helped to reflect a self-organized process and the occurrence of a dissipative structure. This offers valuable insights into our understanding of myocardial protection and could be of considerable interest, especially for heart transplants where the recipient must benefit from the donor's heart in the shortest possible time.
A man in his 30s was involved in a road traffic crash in a small town in India, not equipped to deal with cases of brainstem death. He was declared brain-dead after a few hours. The patient's information was forwarded to organ specialists across the country, with the goal of preserving the patient's organs for donation via a tele-ICU model. The team comprising bedside doctors and remote intensivists communicating via an indigenously developed tele-ICU platform managed the patient for 24 hours, following treatment protocols and providing critical care to ensure that the patient's vital organs were optimally perfused. The following morning, specialist teams from a nearby city arrived at the local hospital to retrieve the patient's organs. This fast-tracked organ retrieval and transplant process were made possible through advances in technology and the involvement of specialists from other parts of the country through this tele-ICU model.
PURPOSE:A lipstick having a humectant action, a clear color, improved adhesion, obtained by dispersing uniformly water or a solution of a water-soluble substance in water into a lipstick by the use of cholesterol, phytosterol phospholipid, or saponin as a dispersant. CONSTITUTION:Water or a solution of a water-soluble subtance in water is uniformly dispersed into a lipstick by the use of one or more of cholrsterol, phytosterol, phospholipid, or saponin as a dipsersant. For example, glycerin, propylene glycol, butylene glycol, sorbitol, etc. of polyhydric alcohol, pyrrolidonecarboxylic acid, water-soluble collagen, keratin, etc. of natural humec tant component, natural viscous substance having strongly humectant action, such as seed polysaccharide, etc. are used as the water-soluble humectant compo nent to provide the skin with wetness. An anionic surface active agent may be used additionally to disperse water more uniformly and stably.
INTRODUCTION: SARS-CoV-2 (COVID-19) infection and multisystem inflammatory syndrome in children (MIS-C) are risk factors for venous thromboembolism (VTE). Guidelines for VTE prophylaxis were established at our institution at the beginning of the pandemic. Patients who had any VTE risk factors in addition to COVID-19 met criteria for anticoagulation prophylaxis. Patients who were diagnosed with MIS-C met criteria regardless of additional risk factors.
MATERIALS AND METHODS: We conducted a retrospective review of patients admitted with COVID-19 or MIS-C to determine compliance with VTE prophylaxis guidelines and to evaluate the incidence of VTE and bleeding events in our population.
RESULTS AND CONCLUSIONS: Among a total of 678 patients admitted with COVID-19 or MIS-C, 519 (76 %) patients met criteria for VTE prophylaxis and 348 (65.6 %) started prophylaxis. Logistic regression analysis identified a personal or family history of thrombosis or thrombophilia, diagnosis of MIS-C, admission to the intensive care unit, and presence of a central venous catheter as significantly associated with starting VTE prophylaxis. There were 18 patients who developed VTE. Minor bleeding events occurred in 19 patients (5 %), patient important bleeding, no intervention occurred in 8 patients (2 %), clinically relevant nonmajor bleeding in 8 patients (2 %), and major bleeding in 10 patients (3 %). The incidence of VTE in our patients with COVID-19 and MIS-C is similar to VTE rates at other institutions. We found that universally recognized VTE risk factors were appropriate to include as risk factors for thrombosis in hospitalized children with COVID-19 and MIS-C.
PURPOSE:To perform economical elimination of pyrogen in higher efficiency in quick and safe manner, by filtering prourokinase through a semipermeable membrane followed by contact of the resulting filtrate with an adsorbent for pyrogen elimination. CONSTITUTION:Firstly, an aqueous solution of purified prourokinase (PUK) (e.g., E. coli-producing gene recombinant PUK with a specific activity >=140,000 unit/mg) containing several thousands - ten thousands ng/ml of endotoxin of several W/V% protein concentration is dissolved in a buffer solution with a pH of ca.5 containing ca.10wt.% of ethanol to prepare a PUK sample solution (A). Secondly, the solution A is filtered through a ultrafilter membrane such as of polystyrene base with a fractional molecular weight of ca.300,000 under such conditions as 11.5-27cm<2> of filtering area based on 50-200ml of the solution A and 2.0-4.5kg/cm<2> of filtering pressure to produce a filtrate (B). Thirdly, a nitrogen-contg. heterocyclic compound (e.g., histamine) is conjugated with a water-insoluble carrier (e.g., cellulose) to prepare an adsorbent for pyrogen adsorption (C). Finally, the solution B is admixed with the adsorbent C in the volume ratio 1:1-1,000 followed by centrifuging or the like, thus recovering a prourokinase solution with the pyrogen eliminated.
Pressure ulcers (PUs) pose a major healthcare challenge and are associated with an increased risk of infection and sepsis, longer hospital stay, and higher hospitalization costs. Their reported incidence in critical care patients varies widely from 1% to 56%. Therefore it is important to take appropriate preventive measures, which can often be successful and less costly than the treatment of established ulcers. Among these measures are the use of pressure-reducing surfaces and repositioning strategies in a protocolized way. Though there is general agreement that critical care patients, including those under mechanical ventilation must use pressure-reducing surfaces, there is no enough evidence in the literature about what is the best repositioning schedule when new, high technology mattresses are used. The use of this new technology has lead to propose that repositioning can be less frequent. In the only clinical trial where this subject (time interval turning) has been addressed (Vanderwee et al, Journal of Advanced Nursing), it is concluded that a turning regimen every 4 hours is equally effective than a 2-hour turning, using this kind of mattresses. Nonetheless this study is not made in critically ill patients, that have more risk factors for developing PUs, the reason we don´t share this findings and recommendations cannot be generalized.

The study hypothesis is that in patients using APAMs, a turning regimen every 2 hour compared to a 4-hour is most effective in the prevention of PUs and could be equally safe.

The objective of this study is to investigate the effect of postural turnings every 2 hours compared to every 4 hours on the incidence of grade \> II pressure ulcers (PU) in patients in ICU on mechanical ventilation (MV) ≥ 24h that use alternating-pressure air mattresses (APAMs) The study is an open label, randomized, controlled clinical trial. The main variable is the incidence of Pus grade ≥ II. As secondary variables measures of efficacy and safety of patients will be registered. The study will take place in a 26 bed medical-surgical ICU with APAMs. Randomization will be done between 24h-48h from the beginning of MV. The final analysis will be by intention to treat.
<P>PROBLEM TO BE SOLVED: To reduce a physician's burden in selecting a schema image.  <P>SOLUTION: A plurality of schema images and characteristic information unique to the schema images are correspondingly stored beforehand. Supplementary information on an object medical image is acquired, and the supplementary information on the object medical image is compared with the characteristic information on the schema images. Based on the compared result, the schema image similar to the object medical image is extracted. Specifically, the schema images are extracted based on a portion first (step S22), and the schema images are further extracted based on a patient direction (step S25), an image direction (step S28), an image position (step S33) and an image area (step S37). A distance between the object medical image and each extracted schema image is computed (step S42), and the candidates of the schema image are given the sequential order from the short one of distances between themselves and the object medical image (step S43).  <P>COPYRIGHT: (C)2009,JPO&INPIT
The invention relates to natural traditional Chinese medicine mask powder as well as a preparation method and a mask thereof. The natural traditional Chinese medicine mask powder is prepared from the following raw materials in parts by weight: 7-23 parts of angelica sinensis, 3-14 parts of radix angelicae, 3-13 parts of radix paeoniae alba, 17-33 parts of bighead atractylodes rhizome, 3-20 parts of common bletilla tuber, and 3-15 parts of white poria. The raw materials also can be further added as follows: 12-28 parts of tribulus terrestris, 1-8 parts of liquorice and 1-8 parts of pearl powder. By cleaning and baking the specific parts of angelica sinensis, radix angelicae, radix paeoniae alba, bighead atractylodes rhizome, common bletilla tuber and white poria, and further added tribulus terrestris, liquorice and pearl powder and grinding into powder, so that a natural traditional Chinese medicine mask is obtained. The natural traditional Chinese medicine mask powder can be further mixed with water or egg white so as to be blended into a paste mask for a user to use. The components are in synergistic interaction, the natural traditional Chinese medicine mask powder is applicable to all types of skin, and is used for improving various skin problems such as acnes, chromatosis and wrinkles, and the product is free of other added ingredients.
Menière's disease is an inner ear disorder with recurrent attacks of vertigo, fluctuating sensorineural hearing loss, tinnitus, and aural fullness. The underlying pathogenetic mechanisms are not known. The pathologic-anatomic correlate of the disease is endolymphatic hydrops, i.e. distension of the endolymphatic spaces as seen at post-mortem microscopic examination of the temporal bone. Prevalence-figures are in the range between 0.1% to 0.5% in the population. In Denmark, the estimated prevalence of Menière's disease is 3500. The disease commonly begins in the fourth or fifth decade of life, and the prevalence increases with age.

There are a great number of different treatment options for Menière's disease including diuretics, sodium-restriction, beta-histidine, and psycho-supportive means, most of which are not validated. The only validated treatment for the vertigo attacks is chemical labyrinthectomy by intra-tympanic injections of the ototoxic antibiotic gentamicin for which two double-blind, placebo-controlled trials found a significant effect. Treatment with gentamicin is ablative, i.e. the goal of the treatment is to destroy the vestibular sensors of the affected ear. This carries a risk of long-standing unsteadiness alongside with permanent hearing loss in the treated ear. Still, no treatments seem to protect from the hearing loss associated with Menière's disease.

The first to advocate the use of transmyringeal ventilation tubes for Menière's disease was Tumarkin in 1966. Tumarkin et al. suggested that negative middle-ear pressure, due to poor tubal function, would lead to a relative over-pressure in the inner ear and that this might be one of the mechanisms behind Menière's disease. In addition, Tumarkin et al. presented several cases where treatment with transmyringeal tubes resulted in relief from vertigo attacks. Hall and Brackmann performed tympanometry in patients with Menière's disease and showed that some, but not all, patients had negative middle-ear pressure and they questioned Tumarkin's suggestions.
Diazepam IntensolTM Oral Solution is a concentrated oral solution as compared to standard oral liquid medications. It is recommended that Diazepam IntensolTM Oral Solution be mixed with liquid or semi-solid food such as water, juices, soda or soda-like beverages, applesauce and puddings.

Use only the calibrated oral syringe provided with this product. Draw into the oral syringe the amount prescribed for a single dose. Then empty the oral syringe contents into a liquid or semi-solid food. Stir the liquid or food gently for a few seconds. The Diazepam IntensolTM Oral Solution formulation blends quickly and completely. The entire amount of the mixture, of drug and liquid or drug and food, should be consumed immediately. Do not store for future use.
BACKGROUND/AIM: Distal extremity misalignment may give rise to pelvic floor dysfunctions (PFDs). This study aimed to compare pelvic floor muscle strength (PFMS) and dysfunctions in women with and without pes planus.
MATERIALS AND METHODS: Women with (pes planus group, n = 30) and without pes planus (control group, n = 30) were included. The presence of PFDs questioned. Pes planus with the Feiss Line Test, PFMS with the Modified Oxford Scale, and the severity of PFDs with the Pelvic Floor Distress Inventory-20 (PFDI-20), including three subscales (Pelvic Organ Distress Inventory-6 (POPDI-6) for pelvic organ prolapse, Colorectal-Anal Distress Inventory-8 (CRADI-8) for colorecto-anal symptoms, and Urinary Distress Inventory-6 (UDI-6) for urinary symptoms, were assessed.
RESULTS: It was seen that no difference was found between groups in terms of PFMS (p > 0.05). However, urinary incontinence and anal incontinence were higher in women with pes planus than in women without pes planus (p < 0.05). Only the PFDI-20, CRADI-8, and UDI-6 scores were higher in women with pes planus compared to controls (p < 0.05). There was no difference was found between groups in terms of POPDI-6 scores (p > 0.05).
CONCLUSION: The PFMS did not change according to the presence of pes planus. However, the prevalence of PFDs and their severity were higher in women with pes planus in comparison to controls. Posture assessments of individuals with PFDs, especially examination of foot posture, and pelvic floor assessments of individuals with posture disorders should be considered.
In patients with type 1 diabetes mellitus, INVOKANA significantly increases the risk of diabetic ketoacidosis, a life-threatening event, beyond the background rate. In placebo-controlled trials of patients with type 1 diabetes mellitus, the risk of ketoacidosis was markedly increased in patients who received sodium glucose transporter 2 (SGLT2) inhibitors compared to patients who received placebo; this risk may be greater with higher doses of INVOKANA. INVOKANA is not indicated for glycemic control in patients with type 1 diabetes mellitus.

Type 2 diabetes mellitus and pancreatic disorders (e.g., history of pancreatitis or pancreatic surgery) are also risk factors for ketoacidosis. There have been postmarketing reports of fatal events of ketoacidosis in patients with type 2 diabetes mellitus using SGLT2 inhibitors, including INVOKANA.

Precipitating conditions for diabetic ketoacidosis or other ketoacidosis include under-insulinization due to insulin dose reduction or missed insulin doses, acute febrile illness, reduced caloric intake, ketogenic diet, surgery, volume depletion, and alcohol abuse.

Signs and symptoms are consistent with dehydration and severe metabolic acidosis and include nausea, vomiting, abdominal pain, generalized malaise, and shortness of breath. Blood glucose levels at presentation may be below those typically expected for diabetic ketoacidosis (e.g., less than 250 mg/dL). Ketoacidosis and glucosuria may persist longer than typically expected. Urinary glucose excretion persists for 3 days after discontinuing INVOKANA [see Clinical Pharmacology (12.2)]; however, there have been postmarketing reports of ketoacidosis and/or glucosuria lasting greater than 6 days and some up to 2 weeks after discontinuation of SGLT2 inhibitors. 

Consider ketone monitoring in patients at risk for ketoacidosis if indicated by the clinical situation. Assess for ketoacidosis regardless of presenting blood glucose levels in patients who present with signs and symptoms consistent with severe metabolic acidosis. If ketoacidosis is suspected, discontinue INVOKANA, promptly evaluate, and treat ketoacidosis, if confirmed. Monitor patients for resolution of ketoacidosis before restarting INVOKANA.

Withhold INVOKANA, if possible, in temporary clinical situations that could predispose patients to ketoacidosis. Resume INVOKANA when the patient is clinically stable and has resumed oral intake [see Dosage and Administration (2.5)] . 

Educate all patients on the signs and symptoms of ketoacidosis and instruct patients to discontinue INVOKANA and seek medical attention immediately if signs and symptoms occur.
The present invention relates to a bolbostemma glucoside A suppository, consisting of bolbostemma glucoside A, tween 80 and suppository ground substance, and in its mixed composition the bolbostemma glucoside A content is 0.5-10%, tween-80 content is 5-10% and the suppsitory ground substance content is 85-94.5%. Its acute toxicity test, accumulative toxicity test, subacute toxicity test and clinical test show that the effective rate of said invention used for curing gynecologic diseases of vaginitis and cervicitis, etc. is 98%, and the effective rate for curing intermediate and late rectal cancer is 76%. Besides, it has no toxic side effect. Said invention also can be used for curing the gynecologic diseases of cervical erosion and cervical polyp, etc. and curing rectitis, etc..
The study investigated the effects of the theory-driven, web-based, computer-tailored intervention to influence workplace sitting on objectively measured sitting time, standing time and breaks from sitting, as well as self-reported context-specific sitting. The computer-tailored advice was compared to a generic advice and a 'no-advice' control at 1-month and 3-months follow-up. The 'tailored' group received a web-based computer-tailored intervention including personalized feedback and tips on how to reduce and/or interrupt workplace sitting. The 'generic' group received a web-based intervention containing generic information and tips to reduce and/or interrupt workplace sitting. The control group was a waitlist control condition and received the generic intervention after completing all measurements. Participants were recruited from a convenience sample of two companies (university and environmental agency) in Flanders (i.e. northern Dutch-speaking part of Belgium), mainly employing desk-based workers, having more than 100 staff members and each having at least three different worksite locations.
Moyamoya disease is a progressive nonatherosclerotic stenosis of the terminal segments of the arteries of the Circle of Willis. Hemorrhagic presentation is a life-threatening condition, associated with an increased risk of rebleeding and ischemic events.1-7 We present the case of a 65-year-old woman with a right intracerebral hemorrhage who underwent emergency hematoma evacuation without bone flap replacement (Video 1). The investigation confirmed the diagnosis of Moyamoya disease and demonstrated hypoperfusion of the right cerebral hemisphere. Late angiography depicted no transdural collaterals through the bone defect and demonstrated preservation of the superficial temporal artery (STA). Next, it was chosen to perform 1-stage cranioplasty with direct revascularization. We detached the temporal fascia from the muscle and created a window through the fascia to give STA passage in a corridor through the temporal muscle until the brain's surface. Vascular anastomosis was performed with an interrupted suture line employing a 10-0 nylon thread. Flow within the right middle cerebral artery was retrograde, coming from branches of the posterior cerebral artery, and the end-to-side anastomosis was placed to orientate the STA flow in the same direction as in the middle cerebral artery. We used a custom-made titanium plate for the cranioplasty and gave enough room inferiorly for the course of STA. In the end, we sutured the temporal fascia to the titanium plate for a better cosmetic result. To avoid additional unnecessary procedures, the performance of direct revascularization during the cranioplasty is feasible and deserves additional investigation as a tool to prevent new hemorrhagic or ischemic events. Informed consent was obtained from the patient for the procedure and publication of this operative video.
The invention relates to a method for changing the operation of the hypothalamus including nasal application of vomerophyrine, e.g. 19-nor holan steroid or a pharmaceutical composition containing it. The vomerophyrine is bound to a specific neuroepithelial receptor. The steroid or steroids are applied, preferably, in the form of a pharmaceutical composition including one or more pharmaceutically acceptable carriers. Another alternative for the implementation of this invention includes pharmaceutical compositions containing the steroids. 41 claims, 2 figures
PURPOSE:To prevent the hydrolysis of an acetal or ketal linkage and thereby obtain a glycerin deriv. compsn. having an improved stability by adding an nonionic surfactant to a glycerin deriv. or a mixture of two or more glycerin derivs. CONSTITUTION:A glycerin deriv. compsn. having an improved stability and useful for a plasticizer, various additives, a solvent, etc., is obtd. by adding a nonionic surfactant of formula III (wherein R<5> is 8-36C alkyl or alkenyl; AO is 2-4C oxyalkylene; and a is an integer of 1-30) to a glycerin deriv. (an acetal or ketal) or a mixture of two or more glycerin derivs. represented by formula I or II (wherein R<1> to R<4> are each H, 1-4C alkyl, or 2-4C alkenyl). The amt. of the surfactant added, though variable with its application, is pref. 0.1-30 pts.wt. based on 100 pts.wt. the deriv.; for diluting with a solvent, the concn. of 0.5wt.% or higher is pref.
PURPOSE:To obtain an antitumor agent having low toxicity and inhibitory effects on multiplication of tumor cell, containing halocynthiaxanthin as an active ingredient in an isolate state or as a natural carotenoid. CONSTITUTION:An antitumor agent containing halocynthiaxanthin as an active ingredient. Natural halocynthiaxanthin usually exists as a mixture of various carotenoids and a carotenoid obtained by extracting especially from Viscum album L. or MAGAKI, concentrating and purifying is preferable. The carotenoid is a red oily substance, has high solubility in oils and has excellent body absorption when administered to human body. Halocynthiaxanthin or a mixture containing halocynthiaxanthin is administered alone or with other medical components by intravenous injection, hypodermic injection, intramuscular injection, oral administration or rectum medication through suppository. Halocynthiaxanthin has also anticancer promoter activity.
The starting dose for Part 2 MAD will be determined by analysis of safety and pharmacokinetic data of Part 1 SAD. All participants will receive RO6889450 orally for 14 days.
The wait-list control group will be instructed to maintain their current health habits and not to engage in any new physical activity or health programs for the next 8-weeks. The wait-list control group will be invited to access the intervention after 8-weeks.